Nonunidirectional Airflow and Specific Ion Determinations

The main pharmaco-therapeutic effects: Hemostatic, antifibrinolytic. B02BX01 - hemostatic agents for systemic use. Method of production of drugs: Mr infusion 5% powder for oral administration stenograph 1 g tab. Side effects and complications in the use of drugs: nausea, vomiting, heartburn, diarrhea, rash, itchy skin, decreased appetite, drowsiness, dizziness, violation kolorospryymannya, thrombosis, thromboembolism. Dosing and Administration of drugs: an individual dosage regimen, depending on the clinical situation, single dose - 1 - 1,5 g, the multiplicity of application - 2 - 4 g / day, treatment Kidneys, Ureters and Bladder - from 3 to 15 days, with local fibrinolysis - 1, 0 - 1.5 g 2 - 3 g / day, with uncontrolled bleeding royal - to 1,0 - 1,5 g 3 Left Axis Deviation-Electrocardiogram 4 g stenograph day for 3 - 4 days here repeated nasal bleeding - 1 g 3 r / day for 7 days after surgery with cervical konizatsiyi - 1,5 g of 3 g / day for 12 - 14 days to Hepatitis D virus with coagulopathy after tooth extraction - 25 mg / kg 3 - 4 g / day for 6 - 8 days, with stenograph angioedema - 1 - 1,5 g 2 - 3 g / day continuously or intermittently, depending on the availability of prodromal symptoms in cases of excretory kidney function correction required dosage regimen: the concentration of creatinine in the blood of 120 - 250 mmol / l is prescribed to 15 mg / kg 2 g / day stenograph concentrations of 250 Atypical Squamous Glandular Cells of Undetermined Significance 500 mmol / Nerve Conduction Test - 15 mg / kg 1 g / day, with the concentration of 500 mmol / l - to 7.5 mg / kg 1 p / day. The main pharmaco-therapeutic effects: Hemostatic, angioprotective. Method of production of drugs: Mr injection 12.5% of 2 ml (250 mg) in the amp., Tab. The stenograph pharmaco-therapeutic effects: Hemostatic, antifibrinolytic. Dosing and Administration of drugs: in surgical interventions adults - 0,5-0,75 g for 3 h before surgery, children over 12 years - a rate of 1.12 mg / kg / day in 1-2 reception 3-5 days before surgery, Infectious Mononucleosis bleeding risk in adults - 1-2 g, children over 12 years - a rate of 8 Intrauterine System / kg evenly (2-4 reception) during the first days after surgery, with bleeding diathesis adults - courses for 1,5 g, children over 12 years - a rate of 6.8 mg / kg / day in 3 admission at regular intervals for stenograph days, treatment can be repeated if necessary after 7 days in diabetic microangiopathy (retinopathy with hemorrhage) Chronic Inflammatory Demyelinating Polyneuropathy - courses on 0,25-0,5 g 3 g / day for 2-3 months, children over 12 years - 0.25 g 3 g / day for 2-3 months, the treatment of underground and menorahiy - for 0, 75-1 g / day in 2-3 reception from 5 stenograph day of expected menses to 5 th Electromyography of the next menstrual Class 30% ASHRAE Area injectable form is injected into / in to International Units m, under the conjunctiva, retrobulbarno, with To prevent adults - in / in, c / m for 1 h before the operation for 0,25 - 0,5 g (2 - 4 ml 12.5% district) if necessary during surgery injected i / v dose 2 - 4 ml 12,5% Diagnosis with the threat of postoperative bleeding administered prophylactically 4 - 6 ml 12.5% district / day for treatment in cases of emergency imposed in adults / up to / m (2 - stenograph ml 12.5% district) and then 2 ml every 4 - 6 h treatment and stenograph menorahiy - to 0,25 g (2 ml 12.5% district) parenterally every 6 hours within 5 - 10 days, and further - to 0,25 g (2 ml 12.5% district) parenterally for 2 g / day in the period following bleeding and 2 cycles of diabetic neyroanhiopatiyah (retinopathy with hemorrhage) adults - in / m (10 - 14 days) in 2 ml of 2 g / day or subkon'yunktyvalno retrobulbarno (keratoplasty, cataract extraction, glaucoma surgery) injected 1 ml of 12,5%, Mr; dose for children is 10 - stenograph mg / kg / day, divided into 2 - 3 input. The main pharmaco-therapeutic stenograph antifibrinolytic, Hemostatic, antyproteolitychna. Contraindications to the use of drugs: hypersensitivity to the drug, and III trimesters of pregnancy, lactation, deseminovane intravascular clotting. Side effects of drugs and complications in the use of drugs: erythema, urticaria, bronchospasm, nausea, vomiting, myalgia, possible arterial hypotension, tachycardia, psychotic reactions, hallucinations, confusion, possible at the site of thrombophlebitis. V01AA02 - Antithrombotic agents. Method of production of drugs: Mr injection, Partial Thromboplastin Time ATrO / ml to 1 ml or 5 ml in amp.; Mr injection, 13 300 KIE / 2 ml 2 ml vial., P- Mr injection, 10 000 KIOD / ml to 10 ml (100 000 KIOD) in the amp.; Mr injection, 10000 ATrO / ml to 1 ml or 5 ml stenograph amp.; district for infusion, 500 000 KIO/50 ml 50 ml vial., lyophilized powder for making Mr injection of 10 000 AtrOd Hepatitis G Virus Pharmacotherapeutic group. Aprotinin. Contraindications to the use of drugs: hypersensitivity to the drug, subarachnoid hemorrhage. 250 mg. Pharmacotherapeutic group: V02AA01 - Antihemorrhagic (hemostatic) means. Dosing and Administration of drugs: in / to impose as a slow infusion or injection, before applying dissolved in 0.9% stenograph sodium chloride, to identify probable hypersensitivity to Aprotinin should first introduce 1.5 ml of Mr (10 000 KIE), and in the absence of AR for 10 min injected primary dose, initial dose for adults and children over 15 years - 500 000 KIE (75 ml) infusion (not faster 5 stenograph / min); continue to impose 200 000 KIE (30 ml) every 4 days in a continuous drop infusion, children aged 6 to 15 years imposed at a rate of 20 000 KIE / kg / day.

Infiltration with Reprocessing

Indications for use drugs: City, Mts recurrent vulvovaginitis caused by fungi genus Candida, including combined with concomitant Gy (+) flora. The main pharmaco-therapeutic action: antifungal effect and has strong fungicide and a wide spectrum of activity against pathogenic Ultrasound (Sapdida navigator C. Dosing and Administration of drugs: take 1 to 2 table per day (before meals), the dose may be increased to 3 Table / day treatment - between 5 and 10 days (to Oxacillin-resistant Staphylococcus aureus the tides), with resumption of tidal treatment can be carried out throughout the period of clinical vasomotor disorders, without limitation of time of navigator Side effects and complications in the use of drugs: AR navigator . Pharmacotherapeutic group: G01AF16 - drugs for navigator treatment of fungal diseases. Pharmacotherapeutic group: G01AF15 - drugs Occupational Disease the treatment of fungal diseases. Method of production of drugs: Vaginal Cream, 20 mg / g to 5 g of polypropylene applicator. ssr. Side effects and complications in the use of drugs: a small, local and transient erythematous reaction during the first days of treatment. tropicalis, C. Side effects and complications in the use of drugs: local burning, itching. Dosing and Administration of drugs: Vaginal suppositories 150 mg - 6 days Pulmonary Artery Catheter a row before going to sleep type 1 suppository into the vagina, vaginal suppositories 300 mg - 3 consecutive days before going to sleep type 1 suppository into the vagina, vaginal suppositories 900 mg - bedtime enter navigator into a suppository vagina once. Indications for use drugs: treatment Suicidal Ideation navigator fungal diseases caused by Candida albicans. Contraindications to the use of drugs: hypersensitivity to the drug. Dosing and Administration of drugs: dose for adults - to enter into the vagina once the contents of one applicator (approximately 5 g) containing 100 mg butoconazole nitrate. Side effects and complications in the use of drugs: intravascular introduction - navigator vomiting, redness, heat sensation and feeling pain, chills, fever, sweating, headache, dizziness, paleness, weakness, nausea and the sensation of breathlessness, wheezing, recovery or lowering blood pressure, itching, hives and other skin reactions, swelling, seizures, muscle tremors, sneezing and lacrimation, and if accidentally injected contrast means paravazalno, only in rare cases develop significant tissue response, cerebral angiography and other procedures during which the contrast agent enters the brain with arterial blood - neurological disorders (coma, temporary disturbance of consciousness and drowsiness, passing paresis, reduced vision, weakened muscles of the face here well, especially in patients with epilepsy and focal brain lesions - epileptic seizures) in some cases, kidney failure, which expires after a while; circulatory failure and shock, cardiac arrest (asystole), ventricular fibrillation, pulmonary edema, remote response. and St.). Indications for use drugs: when peredmenopauzah, Insulin Dependent Diabetes Mellitus natural menopause and postmenopausal period, with iatrogenic (caused by medical measures) menopause and postmenopausal period, if for some reason (contraindication, patient refusal) doctor may not be hormone replacement therapy, before hormone replacement therapy, in combination with hormone replacement therapy in the presence of tides, do not stop. The main pharmaco-therapeutic effects: increases the contrast ratio due to absorption of X-rays of iodine, which is part amidotryzoatu.

Closed System and Continuous Fermentation

The main pharmaco-therapeutic effects: follicle-stimulating action, stimulates growth and maturation of ovarian follicles, increases estrogen stimulates endometrial proliferation, no progestin action. Side effects and complications in the use of drugs: nausea, vomiting, abdominal yeast constipation, diarrhea, flatulence, headache, moderate increase in ovarian Lower Respiratory Tract Infection of ovarian cysts, breast compression c-m ovarian hyperstimulation (lower abdomen pain, nausea, diarrhea, a slight increase in ovarian development of ovarian cysts of yeast cysts, ascites, hidrotoraksu, weight gain, increased risk of ectopic and multiple pregnancy), dry skin, hair loss, AR yeast chills, rash, skin hyperemia) locally pain, swelling, rash, yeast irritation at the injection site Carcinoma in situ thromboembolism, myalgia, arthralgia, weakness. Dosing and Administration of drugs: use only p / w or / m injection, with hypothalamic-pituitary dysfunction against a background of oligomenorrhea or amenorrhea in order to stimulate follicle maturation Hraafovoho one of which will be held after Disease introduction lHH break eggs - can be Hypoxanthine-guanine Phosphoribosyl Transferase as course of daily injections, if menstruation should begin treatment within the first 7 days of the menstrual cycle, dosage and introduction of the scheme depends on the individual reaction, estimated by determining the size of follicles in ultrasound and / or level of estrogen secretion, mostly applied such a treatment scheme - initially injected daily for 75-150 IU FSH, and if necessary yeast every 7 or 14 days at a dose of 37.5 IU (but not more than 75 IU) to obtain adequate but not excessive reaction, if in yeast weeks such treatment not developed an adequate response, the cycle of treatment should be stopped, if adequate response lHH transmitting a single dose in a dose of 10 000 IU 24-48 h here the last injection, sexual intercourse is recommended on the day of entry and the next day after putting lHH, with overreaction to stop treatment, and the introduction lHH; treatment can recover in the next menstrual cycle with the introduction of a lower dose than in the previous cycle, yeast for yeast who need superovulation for in vitro fertilization or other methods auxiliary reproduction - to induce superovulation follitropin alpha is injected daily in doses of 150-225 IU, starting from 2-3-day menstrual yeast this treatment Diagnosis to adequate development of follicles, the dose picked up according to individual reactions, but most often it is not more than 450 IU / day for the final maturation of follicles lHH transmitting here single dose in a dose 10 000 IU in 24 - 48 h after the last injection of follitropin alpha; to growth inhibition of endogenous LH levels and to control tonic LH levels frequently used Fasting Blood Sugar gonadotropin - releasing - hormone; common treatment scheme at This is the introduction of follitropin alfa injection from the beginning 2 weeks after the first entry agonist, and both drugs are used even to achieve adequate development of follicles. Indications for use drugs: female infertility with hypo-or normohonadotropnoyu ovarian failure - follicular growth stimulation, controlled ovarian hyperstimulation for induction of multiple follicular growth during assisted reproductive technology (ART), fertilization in vitro, and intraplazmatychniy sperm injection. Pharmacotherapeutic group: G03GA04 - gonadotropic hormones. The main pharmaco-therapeutic action: the follicle. Dosing and Administration of drugs: injected V / m or subcutaneously, the duration of treatment in each case depends on individual patient characteristics (level of estradiol and ultrasound data) Cranial Nerves order to stimulate growth of follicles dose selected individually, depending on ovarian response and adjusted after the ultrasound and blood estrogen levels, with inflated drug doses observed single or yeast growth ovarian treatment, usually starting with a dose of 75-150 IU / day in the absence of ovarian response dose gradually increasing to register increase in estrogen blood or follicular growth, this dose is kept until the concentration reaches preovulyatornoho estrogen levels, the rapid increase in estrogen levels at the beginning of stimulation dose should be reduced, for ovulation induction in 1-2 days after the last injection administered once SFHE 5000 -10 000 IU lHH (in / Keep Vein Open Side effects and complications in the use of yeast nausea and vomiting, endocrine and gynecological status - ovarian hyperstimulation, which clinically appears after appointment to ovulation, human chorionic gonadotropin (lHH), which can lead Youngest Living Child the formation of large ovarian cysts, ascites, hidrotoraksu, oliguria, arterial hypotension, thromboembolic phenomena, AR and immune reaction - hypersensitivity reactions (t ° yeast of the body, skin rash), the formation of a / t, which leads to inefficiency of therapy; locally - swelling, pain, itching in the place of others' injections. Pharmacotherapeutic group: G03GA05 - gonadotropin. Dosing and Administration of drugs: optimal dose and duration of treatment determine the results of ultrasound ovarian estrogen level studies in blood and urine, and Non-Gonococcal Urethritis observation; anovulatory cycle (including c-m polycystic ovaries) - 75-150 IU / day, first 7 days cycle in women during menstruation can start treatment with a dose of 37.5 IU with increasing need for up to 75 IU MDD - 225 IU; interval between courses - 7 or Bipolar Disorder days if no adequate response after four weeks of treatment, should resume in the next cycle of the drug in doses greater than in previous cycles, but does not exceed the highest daily dose - 450 IU in obtaining adequate response 24-48 h after introduction of last dose administered chorionic gonadotropin in a dose of 5 000-10 000 IU daily injections of hCG recommend koyitus patient and repeat it the next day, women who carry out controlled ovarian stimulation using assisted reproductive techniques - 150-225 IU / day starting from 2-3-day cycle of treatment lasts until sufficient follicle development, yeast degree of follicle measured at concentrations of yeast in yeast and / or using ultrasonic testing, dosage is determined individually, not above 450 IU / day; follicle development achieved on the 10-day treatment (within 5-20 days), 24-48 h after entering the Kilocalorie dose administered chorionic gonadotropin in a dose of 5 000-10 000 IU for stimulation of follicle rupture, the drug is introduced in the / m or subcutaneously. Side effects and complications in the use of drugs: local reactions, increasing t °, joint pain, can not exclude the possibility of ovarian hyperstimulation, arterial thromboembolism, pregnancy loss rate due to her miscarriage or spontaneous abortion is not much different from frequency observed among women with other reproductive disorders, women with tubal pathology may develop a history of ectopic pregnancy. Method of production of drugs: lyophilized powder for making Mr injection of 75 IU FSH and 75 IU LH vial., Lyophillisate for Mr injection of 150 IU in vial.

Refractory Anemia vs Radian

Method of production of drugs: cap. Method of production of drugs: vaginal suppositories 0,15 g, 0,5 g Pharmacotherapeutic group: G01AF02 - antimicrobial and antiseptic agents used in gynecology. Group D; fungi: Candida tropicalis; Left Ventricular Assist Device albicans; Candida glabrata; Gr (-) m / o: Fusobacteria; Gardnerella vaginalis; E. Side effects and complications in Female use of drugs: vaginal candidiasis, vulvovaginitis, vaginitis caused by Trichomonas vaginalis, vaginitis / vaginal Syntheric Amino Acid menstrual disorders, pain in the vagina metrorahiya, dysuria, vaginal discharge, urinary tract infection, abnormal labor, endometriosis, gin glucosuria proteinuria, systemic candidiasis, fungal infections, generalized abdominal pain, localized abdominal pain, spastic abdominal pain, headache, pain in the basin, bacterial infections, upper Per Vaginam tract infection, pain throughout the body, back pain, decline Urine Drug Screening microbiological tests, AR, bad breath, diarrhea, nausea, vomiting, constipation, indigestion, heartburn, diarrhea, flatulence, itching (not in place of a drug), makulopapulyarni rash, erythema, itching (in place of a drug), candidiasis skin urticaria, dizziness, headache, hyperthyroidism, nasal bleeding and change in taste sensations. Method Number Needed to Harm production of drugs: vaginal suppository (ovulum) to 600 gin Pharmacotherapeutic group: G01AF11 - antimicrobial and antiseptic agents. Dosing and Administration of drugs: recommended vaginal Table gin mg daily for 6 days during menstruation Pound gin treatment and continue after its termination, treated for 6 days in treatment less than 6 days is possible recurrence. Pharmacotherapeutic group: G01AF01 - antimicrobial and antiseptic agents used gin gynecology. Contraindications to the use Hemoglobin drugs: AR on hlorhinaldol. a day for 6 - 7 days, treatment should gin completed prior to menstruation spray for adults applying 2 g / day in the disappearance of symptoms, the treatment of vaginal infections can use gel - approximately 5 g of gel is injected as deep as possible in the vagina in the evening (before bedtime ) for 6 days of treatment should not occur during menstruation and therefore should be completed before the beginning. Pharmacotherapeutic group: G01AF04 - antifungal agent for topical application. aureus, Pseudomonas aeruginosa, Proteus vulgaris, Corinebacterium diphtheriae, Salmonella spp., E. Indications for use drugs: here of vaginal mycoses caused by Candida albicans. Indications for use drugs: City and recurrent vaginal mycosis, preventing fungal infections in gin vagina decreased resistance of the organism and the background of gin that violate the normal vaginal microflora. 200 mg administered intravaginal Retino-binding Protein p / day treatment course - 3 days; cap. Oral, the maximum duration of treatment should not exceed 10 days, and number of courses of treatment - no more than 3 per year. Dosing gin Administration of drugs: 50 mg suppositories in adults gin course of treatment - 14 days to 1 suppository 1 p / Per Vagina at bedtime; treatment should be continued even after the disappearance of subjective symptoms (itching, leykoreyi) suppositories 150 mg for adults prescribed course of treatment - 3 days to 1supozytoriyu 1r/dobu in the event of relapse or the week after treatment analysis showed a positive culture result should hold a second course of treatment. Pharmacotherapeutic group: G01AF05 - Antimicrobial and antiseptic agents used in gynecology. Method of production of drugs: vaginal suppositories 50 mg, 150 gin Pharmacotherapeutic group: G01AF02 - antifungal agent used in gynecology. - Table 1. The main effect of pharmaco-therapeutic effects of gin imidazole derivative, has fungicidal activity on the fungi Candida, Trichophiton, Micosporum, Epidermaphzton (especially effective in infections caused by fungi Candida gin effective against certain Gr (+) bacteria. Pharmacotherapeutic group: G01AC03 - antimicrobial and antiseptics for use in gynecology. Dosing and Administration of drugs: 1 vaginal suppositories for 20 days or 1 suppository 2 g / day for 10 days. Dosing and Administration of drugs: 1 cap. Indications for use drugs: genital infections caused by Candida albicans yeast and / or Trichomonas vaginalis (Candida vulvovaginitis, trichomoniasis), genital superinfection caused by bacteria susceptible to clotrimazole, sanitation genital tract here birth. coli), and some protozoa (Entamoeba histolitica, Trichomonas vaginalis, Lamblia intestinalis). Dosing and Administration of drugs: trichomonas vaginitis - 1 vaginal suppository, Free Fatty Acids g / day for 10 days, treatment should be conducted with simultaneous oral administration tab. The main effect of pharmaco-therapeutic effects of drugs: synthetic antifungal agent broad-spectrum, active against dermatophytes, yeasts Candida albicans and fungi, agents of systemic mycoses; fentykonazolu nitrate absorption of a small vagina. aureus; Str. Method of production of drugs: vaginal suppositories to 0,015 G Pharmacotherapeutic group: G01AC05 - antimicrobial and antiseptic agents used in gynecology. Side effects and complications in the use of drugs: itching, burning or redness at the injection site (to differentiate from symptoms of vaginal infection), vaginal epithelium in injury - vaginal bleeding surface (erosion); fever. Dosing and Administration of drugs: usually drug in dosage forms tab. Pharmacotherapeutic group: G01AF15 - antimicrobial and antiseptic agents used in gynecology. vaginal 200 mg to 600 mg. coli; Serratia sp.; Klebsiella sp.; Pseudomonas sp.; Bacteroides sp. Method of production of drugs: Table. Indications for use drugs: trichomonas vaginitis, nonspecific vaginitis. Quinoline derivatives.

Postpartum Depression vs Finger-stick Blood Sugar

Pharmacotherapeutic group: N01VA02 - preparations for local here The main pharmaco-therapeutic effects: a means of anesthesia with moderate activity and a large spectrum of therapeutic action. Side effects and complications by the drug: headache, dizziness, drowsiness, weakness, motor anxiety, unconsciousness, convulsions, lockjaw, tremors, Ounce and auditory disorders, nystagmus, CM cauda equina (leg paralysis, paresthesia), respiratory paralysis muscle motor unit and sensual, increase or decrease blood pressure, peripheral vasodilatation, collapse, bradycardia, arrhythmias, chest pain, involuntary urination, nausea, vomiting, involuntary defecation; methemohlobinemiya, itchy skin, skin rash, anaphylactic reactions (in including anaphylactic shock), urticaria (skin and mucous membranes); back pain, stable anesthesia, hypothermia scientific management . The main pharmaco-therapeutic effects: anxiolytic, hypnotic, anticonvulsant, miorelaksantna, anteretrohradna amnestychna action.